ArticleJournal of dental sciences2025
Corylin ameliorates inflammaging and pyroptosis in diabetic periodontitis: A preliminary
Article in Journal of dental sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Diabetic periodontitis (DP) is a severe oral disease characterized by hyperinflammation and impaired wound healing, with inflammaging and pyroptosis playing key roles in its pathogenesis. Corylin, an isoflavone compound, has shown promising anti-inflammatory and anti-pyroptotic properties, but its specific effects on DP remain largely unexplored. This study aimed to evaluate the effects of Corylin on inflammaging and pyroptosis in an in vitro model of DP, potentially offering novel insights into therapeutic strategies for this challenging condition. Materials and methods: This in vitro study evaluated the effects of Corylin on inflammaging and pyroptosis in human gingival fibroblasts (HGFs) exposed to advanced glycation end products (AGEs) to mimic the diabetic environment. We then examined the reactive oxygen species (ROS) generation and wound healing ability in the cells. To assess the inflammaging, we probed into cell senescence activity and senescence marker p16 as well as its senescence associated secretory phenotype (SASP) such as interleukins (IL)-6 and IL-8. Next, we measured the levels of pyroptosis markers including nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3), apoptosis-associated speck-like protein containing a CARD (ASC), caspase-1 in cells with and without Corylin. Results: Corylin reduced ROS production and enhanced wound healing in AGEs-treated HGFs in a dose-dependent manner. Furthermore, Corylin attenuated the heightened inflammaging markers, which included cellular senescence and the secretion of SASP, IL-6 and IL-8. Additionally, Corylin downregulated the expression of pyroptosis-related components, including NLRP3, ASC, and caspase-1, in AGEs-treated HGFs. Conclusion: These findings suggest that Corylin may have therapeutic potential in DP by mitigating AGE-induced inflammaging and pyroptosis. Corylin's ability to promote wound healing and inhibit both cellular senescence and pyroptosis highlights its potential as a novel therapeutic agent for DP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.